Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Fianna Fáil TD defends controversial pharma Bill

By Mindo - 14th May 2018 | 19 views

Deputy John Brassil had introduced the Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2018, which proposes that “guidelines which include a threshold incremental cost-effective ratio or similar assessment shall not be relevant in the case of orphan medicinal products”.

Clinical Director of the National Centre for Pharmacoeconomics (NCPE) Prof Michael Barry told the recent IMO AGM he “nearly fell on the floor” when he saw the proposal. Prof Barry said the proposal would mean industry would not be compelled to “prove” such drugs are value for money. He added that cost-effectiveness analyses facilitated the HSE to negotiate reduced prices. Deputy Brassil, who is Fianna Fáil Spokesperson for Primary Care and Community Health Services, told the <strong><em>Medical Independent</em></strong> (<strong><em>MI</em></strong>) his Bill relates to drugs for rare and ultra-rare diseases involving patient populations of less than 10 or between 10 and 50.

“Rather than having the quantitative approach, they should look at the qualitative approach, because you can’t gather the data necessary when you have such a small population pool to satisfy the criteria they use at the moment; therefore, the companies now aren’t even bothering to apply to the Irish system and some of these drugs are actually made in Ireland,” he stated.

<img src=”../attachments/eb3dbc0f-2989-4ea7-a995-3d751278dbcd.JPG” alt=”” />

<strong>Deputy John Brassil</strong>

He said he understood there is a limited health budget but argued that patients only gained access to these types of drugs through protesting.

Deputy Brassil added: “I have met with all the different drug companies, for the various products, since I got elected but nobody in particular has lobbied me. Everybody has lobbied me, but nobody in particular, if you know what I mean.”

Leave a Reply

Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read